

<b>Supporting Table 2. Demographic and selected clinical features by study group</b>			
	<b>IMI† (n=18)</b>	<b>Non-IFI (n=16)</b>	<b>χ<sup>2</sup>, df (P value)</b>
<b>Age</b>			
Older than 40 years, n (%)	15 (83.3)	13 (81.2)	<b>0.025, 1 (0.874)</b>
<b>Sex</b>			
Male, n (%)	12 (66.7)	10 (62.5)	<b>0.064, 1 (0.800)</b>
<b>Hematological malignancy, n (%)</b>			
ALL	3 (16.7)	5 (31.2)	<b>3.060, 3 (0.383)</b>
AML/MDS	14 (77.8)	10 (62.5)	
CMML	1 (5.6)	0 (0)	
NHL	0 (0)	1 (6.2)	
<b>Disease status, n (%)</b>			
Not in remission	3 (16.7)	3 (18.8)	<b>1.732, 2 (0.421)</b>
Relapse	4 (22.2)	1 (6.2)	
Remission°	11 (61.1)	12 (75.0)	
<b>Type of HSCT, n (%)</b>			
Autologous	0 (0)	1 (6.2)	<b>2.267, 4 (0.687)</b>
Double cord blood	1 (5.6)	0 (0)	
Matched related	2 (11.1)	1 (6.2)	
Matched unrelated	3 (16.7)	3 (18.8)	
<b>Neutropenia*</b>			
n (%)	13 (72.2)	14 (87.5)	<b>1.209, 1 (0.271)</b>
<b>Graft-versus-host disease</b>			
n (%)	5 (27.8)	4 (25.0)	<b>0.034, 1 (0.855)</b>
<b>Steroid use</b>			
n (%)	5 (27.8)	3 (18.8)	<b>0.384, 1 (0.536)</b>
<b>CMV reactivation**</b>			
n (%)	3 (16.7)	4 (25.0)	<b>0.360, 1 (0.549)</b>

IMI, invasive mold infection; non-IFI, non-invasive fungal infection; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; CMML, chronic myelomonocytic leukemia.

†This group includes invasive aspergillosis and mucormycosis patients. Remission defined as <5% blasts on bone marrow biopsy after induction chemotherapy. \*Neutropenia defined as absolute neutrophil count (ANC) <0.5 × 10<sup>9</sup>/L. \*\*CMV reactivation defined as blood CMV DNA level in peripheral blood >100IU/ml in two occasions within the 12 months prior to data of sample collection.